Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2021 | 1L NALIRIFOX in advanced or metastatic PDAC

Zev Wainberg • 1 Jul 2021
ESMO WCGIC 2021
Gastrointestinal Cancer Pancreatic Cancer 5-fluorouracil Leucovorin Liposomal irinotecan NALIRIFOX Oxaliplatin

Zev A. Wainberg, MD, Msc, UCLA School of Medicine, LA, CA, discusses findings of a Phase I/II study evaluating the safety and efficacy of first-line (1L) liposomal irinotecan + oxaliplatin + 5-fluorouracil + leucovorin (NALIRIFOX) in patients with pancreatic ductal adenocarcinoma (mPDAC). First-line NALIRIFOX for patients with locally advanced/mPDAC was generally manageable and tolerable, and a randomized, controlled Phase III study is underway. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.

More from Zev Wainberg

0:43
daNIS-2: NIS793 with nab-paclitaxel and gemcitabine in mPDAC
Zev Wainberg • 20 Jan 2023
0:32
DKN-01 with bevacizumab and chemotherapy in advanced CRC
Zev Wainberg • 20 Jan 2023
0:54
NAPOLI-3: first-line NALIRIFOX in metastatic pancreatic ductal adenocarcinoma
Zev Wainberg • 20 Jan 2023
0:48
Current and future directions in gastric cancer research
Zev Wainberg • 12 Apr 2022

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals